Hedgehog Pathway Inhibition

Aleksandar Sekulic; Daniel Von Hoff

doi:10.1016/j.cell.2016.02.021

Hedgehog Pathway Inhibition

Aleksandar Sekulic, Daniel Von Hoff

Dermatology

Research output: Contribution to journal › Short survey › peer-review

38 Scopus citations

Abstract

The hedgehog (Hh) signaling pathway is aberrantly activated in a majority of basal cell carcinomas (BCC). Vismodegib and sonidegib are targeted inhibitors of Smoothened (SMO). Both drugs are approved for use in locally advanced BCC (laBCC), with vismodegib also approved for metastatic BCC (mBCC).

Original language	English (US)
Pages (from-to)	831
Number of pages	1
Journal	Cell
Volume	164
Issue number	5
DOIs	https://doi.org/10.1016/j.cell.2016.02.021
State	Published - Feb 25 2016

ASJC Scopus subject areas

General Biochemistry, Genetics and Molecular Biology

Access to Document

10.1016/j.cell.2016.02.021

Cite this

@article{96785cbec1c044809faae5a21f763855,

title = "Hedgehog Pathway Inhibition",

abstract = "The hedgehog (Hh) signaling pathway is aberrantly activated in a majority of basal cell carcinomas (BCC). Vismodegib and sonidegib are targeted inhibitors of Smoothened (SMO). Both drugs are approved for use in locally advanced BCC (laBCC), with vismodegib also approved for metastatic BCC (mBCC).",

author = "Aleksandar Sekulic and {Von Hoff}, Daniel",

note = "Publisher Copyright: {\textcopyright} 2016 Elsevier Inc.",

year = "2016",

month = feb,

day = "25",

doi = "10.1016/j.cell.2016.02.021",

language = "English (US)",

volume = "164",

pages = "831",

journal = "Cell",

issn = "0092-8674",

publisher = "Cell Press",

number = "5",

}

TY - JOUR

T1 - Hedgehog Pathway Inhibition

AU - Sekulic, Aleksandar

AU - Von Hoff, Daniel

PY - 2016/2/25

Y1 - 2016/2/25

N2 - The hedgehog (Hh) signaling pathway is aberrantly activated in a majority of basal cell carcinomas (BCC). Vismodegib and sonidegib are targeted inhibitors of Smoothened (SMO). Both drugs are approved for use in locally advanced BCC (laBCC), with vismodegib also approved for metastatic BCC (mBCC).

AB - The hedgehog (Hh) signaling pathway is aberrantly activated in a majority of basal cell carcinomas (BCC). Vismodegib and sonidegib are targeted inhibitors of Smoothened (SMO). Both drugs are approved for use in locally advanced BCC (laBCC), with vismodegib also approved for metastatic BCC (mBCC).

UR - http://www.scopus.com/inward/record.url?scp=84959421964&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84959421964&partnerID=8YFLogxK

U2 - 10.1016/j.cell.2016.02.021

DO - 10.1016/j.cell.2016.02.021

M3 - Short survey

C2 - 26919418

AN - SCOPUS:84959421964

SN - 0092-8674

VL - 164

SP - 831

JO - Cell

JF - Cell

IS - 5

ER -

Hedgehog Pathway Inhibition

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this